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 Introduction 
 The dystonias are a common but heterogeneous group 
of movement disorders. Mutations in the thanatos-asso-
ciated protein domain containing apoptosis-associated 
protein 1  (THAP1) gene on chromosome 8p21-q22 have 
been identified as a cause of adult-onset isolated dystonia 
(DYT6). This condition has been recently classified as an 
isolated dystonia in which dystonia is the main clinical 
manifestation with the exception of tremor  [1, 2] . DYT6 
dystonia is an autosomal dominantly inherited condition 
with a heterogeneous phenotypic spectrum reported 
across genetically diverse populations and ethnicities, 
with both craniocervical and upper limb onset described 
 [1, 3–5] .
 Pathophysiological studies of dystonia have concen-
trated specifically on the basal ganglia owing to the evi-
dence from the combined dystonias, where dystonia oc-
curs in conjunction with other neurological disorders. 
However, recent studies have also provided evidence of 
cerebellar abnormalities in isolated dystonias  [6, 7] . In 
humans, THAP1 is widely expressed in the brain and in a 
wide variety of extraneural tissues such as the liver, kid-
ney, skeletal muscle, thyroid gland and prostate  [8] . In a 
mouse model, the highest levels of expression are ob-
served in cerebellar Purkinje cells, the dentate gyrus, hip-
pocampal pyramidal cells and the cerebral cortex  [8] . In 
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 Abstract 
 Background: Mutations in the thanatos-associated protein 
domain containing apoptosis-associated protein 1 gene 
( THAP1 ) are responsible for adult-onset isolated dystonia 
(DYT6). However, no neuropathological studies of geneti-
cally proven DYT6 cases have been previously reported.  Ob-
jective: We report the first detailed neuropathological inves-
tigation carried out on two DYT6 brains.  Methods: Genetic 
screening for  THAP1 gene mutations using standard Sanger 
polymerase chain reaction sequencing identified 2 cases, 1 
with a known pathogenic mutation and the other with a 
novel mutation. A detailed neuropathological assessment of 
the cases was performed.  Results: Both DYT6 cases showed 
no significant neurodegeneration and no specific disease-
related pathology.  Conclusions: No neuropathological fea-
tures that could be defined as hallmark features of DYT6 dys-
tonia were identified. Our study supports the notion that in 
isolated dystonia, there is no significant neurodegeneration 
or morphological lesions that can be identified using routine 
methods.  © 2015 S. Karger AG, Basel 
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rats, the neurodevelopmental expression pattern of a 
Thap1 transcript was higher in the brain than in the spi-
nal cord at early stages but later declined to similar levels. 
In the cerebellum, however, it remained high throughout 
adulthood  [9] .
 There have been few neuropathological descriptions 
of isolated dystonia cases. Based on routine neuropatho-
logical techniques, most studies did not identify specific 
abnormalities  [10] . Perhaps the most interesting finding 
in isolated dystonia has been a neuropathological study 
of genetically confirmed DYT1 cases in which intraneu-
ronal inclusions immunoreactive for ubiquitin, torsin A 
and lamin A/C were identified in brainstem nuclei, al-
though this observation has never been replicated  [11] . 
The aim of this study is to report a neuropathological 
study of 2 previously unreported genetically confirmed 
DYT6 cases. There have been no other neuropathological 
descriptions of cases with  THAP1 pathogenic mutations 
to our knowledge.
 Materials and Methods 
 Cases 
 This project was approved by the Joint Local Research Ethics 
Committee of the National Hospital for Neurology and Neurosur-
gery and the UCL Institute of Neurology. Formalin-fixed, paraffin-
embedded brain tissue was received from the Brain and Tissue 
Banks for Developmental Disorders (BTBDD), Baltimore, Md., 
USA (case 1) and formalin-fixed brain tissue of case 2 was pro-
vided by the Harvard Brain Bank. Clinical details were provided 
by the respective institutions. To our knowledge, neither of the 
cases had been previously reported. Where possible, the frontal, 
temporal and parietal cortices, hippocampus, striatum, globus pal-
lidus, thalamus, subthalamic nucleus, cerebellum, midbrain, pons 
and medulla were investigated.
 Genetics 
 DNA was extracted from frozen brain tissue (cerebellum) using 
a DNeasy Blood and Tissue Kit (Cat. No. 69504). Cases were se-
quenced for the sequence variants in the three exons of the  THAP1 
gene (ENST00000254250) using standard Sanger sequencing, as 
previously described  [4] .
 Immunohistochemistry 
 Paraffin-embedded tissue sections (7 μm) were stained using 
hematoxylin and eosin (HE), Gallyas silver and Luxol fast blue/
cresyl violet. Immunohistochemistry (IHC) was performed as pre-
viously described  [11, 12] . Antibodies used included the following: 
ubiquitin (1: 200; Dako, Ely, UK), tau (1: 600, AT8; Autogen Bio-
clear, Calne, UK); GFAP (1: 1,000; Dako), Aβ (1: 200; Dako), 
α-internexin (1: 75, 967654; Abcam), α-synuclein (1: 50; Novacas-
tra, Newcastle, UK), α-synuclein (1: 1000; BD Transduction Bio-
labs, Oxford, UK), p62 (1: 100; BD Bioscience, Oxford, UK), CD68 
(1: 150; Dako) and TDP-43 (1: 2000; Proteintech, Manchester, UK).
 Neuropathological Assessment 
 A detailed neuropathological study was carried out on both cas-
es for the brain regions available. Semiquantitative assessment of 
neuronal loss and gliosis was performed using HE staining, GFAP 
and α-internexin IHC, respectively. The midbrain and pons were 
stained with antibodies to ubiquitin and p62 to assess the presence 
of intraneuronal inclusions in the periaqueductal gray matter, pe-
dunculopontine nucleus, cuneiform nucleus and reticular forma-
tion where available  [11] . The Aβ cortical plaques were assessed 
based on the criteria of the Consortium to Establish a Registry for 
Alzheimer’s disease  [13] . Other concomitant pathological condi-
tions, including tau, cerebral amyloid angiopathy, TAR DNA-
binding protein (TDP-43), α-synuclein pathology and small vessel 
disease, were assessed using published criteria  [13–17] .
 Results 
 Clinical and Genetic Data 
 Demographic and clinical data are summarized in  table 1 .
 Case 1 was a Caucasian male with an onset of dystonia 
at the age of 17 which became severe. Later in life he de-
veloped seizures and chronic obstructive pulmonary dis-
ease and was thought to have multi-infarct dementia. Ge-
netic testing was negative for DYT1 dystonia. He died 
following two seizures at the age of 71. A single heterozy-
gous mutation, p.R29Q, in the coding region of  THAP1 
 was found. This mutation has previously been described 
as pathogenic in DYT6  [5, 8] .
 Case 2 was a 59-year-old male with a clinical diagnosis 
of dystonia. No further clinical details were available. A 
 Table 1.  Demographic and clinical details of DYT6 cases
Case Sex Ethnicity Clinical diagnosis DYT6
variant
Age at onset,
years
Age at death,
years
Cause of
death
1 male American Caucasian dystonia, affected p.R29Q 17 71 seizures
2 male American Caucasian dystonia, affected p.S21F N/A 59 N/A
 N/A = Not available.
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novel heterozygous variant, p. S21F, predicted to be dis-
ease causing (Mutation Taster score: 155, PolyPhen score: 
0.981 and SIFT score: 0.01) was identified. The amino ac-
ids involved in each case are conserved across several spe-
cies.
 Neuropathological Assessment 
 A summary of the pathological findings is given in  ta-
ble 2 with details of the regional histological assessment 
provided in  table 3 .
 Macroscopic Findings 
 Macroscopic findings were derived from the report 
provided by the BTDBB for case 1 and by direct observa-
tion of the brain slices provided for case 2. In case 1 
mild-to-moderate generalized cerebral atrophy was de-
scribed. The blood vessels of the circle of Willis showed 
moderate atherosclerosis with no vascular anomalies. 
The cortical ribbon was of slightly reduced thickness 
and the hippocampal formation was mildly atrophic. 
Patchy areas of acute ischemia were observed in the deep 
 Table 2.  Summary of neuropathological findings in DYT6 cases
Case Macroscopic features  Aβ pathology Tau
pathology
Lewy body
pathology
SVD CAA TDP-43
pathologyD  M
1 Mild-to-moderate cerebral atrophy
Mild cortical and hippocampal atrophy
Patchy acute ischemic lesions 
+++ + + – + + –
2 No abnormalities + – - – – ++ –
 Macroscopic features were derived from the neuropathology report issued by the BTDBB for case 1 and by direct observation for 
case 2. – = Absent; + = mild; ++ = moderate; +++ = severe; SVD = small vessel disease; CAA = cerebral amyloid angiopathy; D = diffuse; 
M = mature.
 Table 3.  Semiquantitative summary of neuropathological changes in DYT6 cases
Regions Case 1 Case 2
neuronal
loss
gliosis  Aβ Lewy
bodies
tau CAA TDP-43 neuronal
loss
gliosis Aβ Lewy
bodies
tau CAA TDP-43
D M D M
Cortex
Frontal – + +++ + – – + N/P – – NP NP N/P N/P N/P N/P
Motor N/A N/A N/A N/A N/A N/A N/A – – N/P N/P N/P N/P N/P
Temporal – + + – – + + N/P – – – – N/P – N/P N/P
Parietal N/A N/A N/A N/A N/A N/A N/A – – + – – ++ N/P
Hippocampal formation N/A N/A N/A N/A N/A N/A N/A – – N/P – – N/P N/P
Caudate – – N/P N/P – N/P – – – N/P N/P – N/P –
Putamen – + N/P N/P – N/P – – – N/P N/P – N/P –
Globus pallidus – + N/P N/P – N/P – – – N/P N/P – N/P –
Thalamus N/A N/A N/A N/A N/A N/A N/A – – N/P N/P – N/P N/P
Subthalamic nucleus N/A N/A N/A N/A N/A N/A N/A – – N/P – – N/P N/P
Substantia nigra N/A N/A N/A N/A N/A N/A N/A + – – – – N/P N/P
Locus coeruleus N/A N/A N/A N/A N/A N/A N/A – – N/P – N/P N/P N/P
Pontine nuclei N/A N/A N/A N/A N/A N/A N/A – – N/P – N/P N/P N/P
Dorsal motor nucleus of vagus – ++ N/P – – N/P N/P N/A N/A N/A N/A N/A N/A N/A
Twelfth nerve nucleus – ++ N/P – – N/P N/P – – N/P – N/P N/P N/P
Inferior olive – ++ N/P – – N/P N/P – – N/P – N/P N/P N/P
Cerebellar Purkinje cells + + N/P N/P – N/P N/P + + N/P N/P – N/P N/P
Dentate nucleus – + N/P N/P – N/P N/P – – N/P N/P – N/P N/P
 – = Absent; + = mild; ++ = moderate; +++ = severe; D = diffuse plaques; M = mature plaques; N/A = not available; N/P = not performed; CAA = cerebral 
amyloid angiopathy.
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gray matter structures. Case 2 showed no macroscopic 
abnormalities. The cortical ribbon, caudate, putamen, 
thalamus, subthalamic nucleus, globus pallidus, hippo-
campus, cerebellum, pons and medulla were all unre-
markable. There were no focal lesions and no brain at-
rophy was observed.
 Histology 
 The histological features are illustrated in  figure 1 . In 
case 1 the cortex, cerebellum, dentate nucleus, basal gan-
glia, substantia nigra and medulla were well preserved 
with no detectable neuronal loss, with the exception of 
mild Purkinje cell depletion with occasional axonal tor-
a b
c d
e f
g h
 Fig. 1. Histological examination of the pu-
tamen ( a ), subthalamic nucleus ( c ), locus 
coeruleus ( d ) and hippocampus ( e ) of case 
2 showed no appreciable neuronal loss, al-
though there was mild loss of pigmented 
neurons in the substantia nigra ( b ). In case 
1, there were frequent cortical diffuse and 
sparse mature Aβ deposits ( f , frontal cor-
tex). There was mild Purkinje cell depletion 
in the cerebellum ( g ) with occasional axo-
nal torpedoes ( h ).  a–e ,  g HE stain.  f Aβ 
IHC.  h α-Internexin IHC. Scale bar in  a 
represents 500 μm in  e , 100 μm in  f and  g 
and 50 μm in  a–d and  h . 
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pedoes ( fig. 1 g, h). There was mild-to-moderate gliosis 
in several brain regions ( table 3 ). Aβ deposits were most 
frequent in the frontal cortex where there were frequent 
diffuse and sparse mature plaques ( fig. 1 f). There was 
also mild cerebral amyloid angiopathy. Tau pathology of 
Alzheimer type (neurofibrillary tangles, neuropil threads 
and abnormal neurites) was mild in the temporal cortex 
but was not observed in subcortical regions. Formal 
analysis of the Aβ Thal phase and Braak and Braak tau 
staging was not possible due to the limited regions avail-
able for examination (brain regions available for study 
and observations in each case are provided in  table 3 ). 
There was no α-synuclein pathology in the form of ei-
ther Lewy bodies or glial cytoplasmic inclusions and no 
TDP-43 immunoreactive inclusions were found. There 
was mild small vessel disease but no further evidence of 
vascular lesions. We sought to identify pathological neu-
ronal cytoplasmic inclusions in the midbrain and pons 
as described previously in DYT1 dystonia cases using 
ubiquitin and p62 IHC; however, such inclusions were 
not identified.
 In case 2 no neuronal loss was observed except for 
mild loss of pigmented neurons in the substantia nigra 
( fig. 1 b) and mild Purkinje cell depletion. Gliosis was re-
stricted to the cerebellar cortex where it was of mild de-
gree. Alzheimer pathology in the form of cortical Aβ de-
position was observed in the parietal cortex where there 
were sparse diffuse deposits. There was moderate cere-
bral amyloid angiopathy in the parietal lobe. No tau im-
munoreactive inclusions were found in any region. Care-
ful examination of the midbrain and pons showed no 
p62- or ubiquitin-labelled neuronal cytoplasmic inclu-
sions. No α-synuclein or TDP-43 pathology was found 
and there was no evidence of small vessel disease.
 Discussion 
 The molecular genetics of isolated dystonia syn-
dromes have been the subject of extensive analysis and a 
number of genes associated with autosomal dominant 
inheritance have now been identified. Despite these ge-
netic advances which shed light on the disease pathogen-
esis, there are few neuropathological descriptions of iso-
lated dystonia in the literature and the neuropathology 
of DYT6 has not previously been described. In this study 
we undertook detailed neuropathological assessment of 
2 DYT6 cases with confirmed  THPA1 mutations and 
could find no disease-specific morphological abnormali-
ties.
 Both cases had missense mutations in the THAP1 
domain of  THAP1 , p. R29Q and a novel mutation p. 
S21F, respectively. The heterogeneity in the clinical 
spectrum of DYT6 dystonia is growing owing to the 
number of  THAP1  mutations reported in the literature 
since the gene discovery. This has made it difficult to 
establish a genotype-phenotype correlation in terms of 
clinical phenotypes reported for DYT6 cases. However, 
functional studies were more successful in demonstrat-
ing the mutation effect. Mutations in the THAP1 do-
main are thought to interrupt DNA binding, causing 
transcriptional dysregulation of THAP1 target genes 
 [1] . A functional study in a THAP1 case with a frame-
shift mutation in the nuclear localizing signal region of 
 THAP1 demonstrated an impaired nuclear import of 
mutant THAP1 in vitro  [18] ; THAP1 is reported to in-
teract with the promoters of  TOR1A , mutations of 
which cause DYT1 dystonia  [19] ,  TAF1 , implicated in 
DYT3 dystonia  [20] , and recently THAP1 has been re-
ported to autoregulate its own expression  [21] . Hence, 
studies of biochemical and cellular mechanisms may 
provide a link to abnormal motor control in DYT6 dys-
tonia.
 Our neuropathological investigation of these DYT6 
cases utilized a similar IHC approach to that previously 
applied in DYT1-related dystonia cases  [11, 12] and 
adult-onset dystonia cases  [22] with the specific aim of 
determining whether brainstem neuronal cytoplasmic 
inclusions are a common hallmark of isolated dystonias 
 [11] . We were unable to identify such inclusions in our 
study and, indeed, we found no neuropathological fea-
tures that could be regarded as specific to DYT6 dysto-
nia in either case. This study adds further evidence that 
morphological abnormalities detectable using current 
neuropathological techniques are not features of isolat-
ed dystonias. Further biochemical and molecular biol-
ogy studies may provide an understanding of the patho-
genesis of isolated dystonia.
 Conclusion 
 This study provides the first ever detailed neuro-
pathological study on two DYT6 brains. Our observa-
tions suggest that there were no detectable disease-spe-
cific morphological abnormalities in DYT6 dystonia 
using current neuropathological techniques. This study 
highlights the importance of cellular and biochemical 
studies in understanding the pathogenesis of isolated 
dystonia.
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